With nearly 30 active clinical trials for advanced and/or rare cancers, TCRS is one of the leading centers for Phase I oncology trials in the nation. Clinical trials with agents directed at specific targets in patients' tumors were launched in November 2005. These clinical trials give options that did not exist before to Phoenix-area patients as well as patients from all over the country. TCRS is conducting clinical trials across a number of cancer types. Further development of cancer specific divisions in pancreatic cancer, breast cancer, leukemia, prostate cancer, lung cancer, and melanoma are under development.

In addition to clinical trials, a molecular profiling pilot study has been designed and implemented to test the hypothesis that treatment with a cancer agent selected based on the unique molecular profile of a patient's tumor may be more beneficial than a treatment selected based on the specific cancer type.

Patient participation in clinical trials is a necessary component to the research process. According to the National Institutes for Health, only 3% of adults with cancer are participating in clinical trials. At TCRS, the clinical trial participation rate is a remarkable 60%. Interestingly, a recent study shows that if given the opportunity and access to clinical trials, 63% of the population would participate, according to a survey by the Charlton Research Co.

Patient participation in clinical trials at TCRS includes:

- 125 visits per month

- 35-45 new patients per month

- 400-600 patient samples collected per month

For ALL patients inquiring about a particular study, please contact patient care coordinator, Joyce Schaffer.

Joyce Schaffer RN MSN OCN
Patient Care Coordinator
TGen Clinical Research Services @ SHC
Debi & Jerry Bisgrove Research Pavilion
10510 N. 92nd Street, Suite 200
Scottsdale, AZ 85258
Office 480-323-1339 or 1-877-273-3713
Fax 480-323-1276
Alternative Fax 480-323-1359
joschaffer@shc.org

Current Active Studies

ADRENOCORTICAL CARCINOMA

1. A Randomized, Double-blind, Placebo-controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma http://www.clinicaltrials.gov/ct2/show/NCT00924989?term=osi906&rank=4

   BASAL CELL CARCINOMA

2. A Single Arm Open Label Expanded Access Study of GDC-0449 in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma http://www.clinicaltrials.gov/ct2/show/NCT01160250?term=gdc-0449&rank=2
3. A Phase 1 Study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies http://www.clinicaltrials.gov/ct2/show/NCT00761696?term=ipi926&rank=1

   BREAST CANCER

4. A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray http://clinicaltrials.gov/ct2/show/NCT01074814?term=SIDEOUT&rank=1

   LYMPHOMA

5. A Phase I Study of AR-12 in Adult Patients with Advanced or Recurrent Solid Tumors or Lymphoma, for Which No standard Therapy is Available http://www.clinicaltrials.gov/ct2/show/NCT00978523?term=ar-12&rank=1

6. A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Solid Tumors or Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00688415?term=VTX-2337&rank=1

   MEDULLOBLASTOMA/CHONDROSARCOMA

7. A Phase 1 Study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies http://www.clinicaltrials.gov/ct2/show/NCT00761696?term=ipi926&rank=1

   MELANOMA

8. A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynmaic Study of E6201 Administered Once Weekly for 3 Weeks (days 1, 8, and 15 of a 28-day Cycle) in Subjects with Melanoma http://www.clinicaltrials.gov/ct2/show/NCT00794781?term=e6201&rank=2

   PANCREATIC CANCER

9. A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas http://www.clinicaltrials.gov/ct2/show/NCT00844649?term=abi+gem+pancrease&rank=1

10. A Phase I, Open-Label, Dose Escalation Study of ASG-5ME in Patients with Pancreatic Adenocarcinoma http://www.clinicaltrials.gov/ct2/show/NCT01166490?term=ASG-5ME&rank=1

11. A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer http://www.clinicaltrials.gov/ct2/show/NCT00839332?term=ly2603618&rank=1

12. A Phase II Study of Coagulation Factor VIIA Inhibitor PCI-27483 In Pancreatic Cancer Patients http://www.clinicaltrials.gov/ct2/results?term=pcI-27483

    THYMIC CANCER

13. A Phase II Study of oral PHA-848125AC I patients with Thymic Carcinoma Previously treated with chemotherapy http://www.clinicaltrials.gov/ct2/show/NCT01011439?term=pha-848125ac&rank=1

    THYROID – MEDULLARY

14. An International, Randomized, Double-blinded, Phase III Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer http://www.clinicaltrials.gov/ct2/show/study/NCT00704730?term=xl184&recr=Open&cond=thyroid&rank=2&show_locs=Y#locn

    SOLID TUMORS

15. A Phase I Study of AR-12 in Adult Patients with Advanced or Recurrent Solid Tumors or Lymphoma, for Which No standard Therapy is Available http://www.clinicaltrials.gov/ct2/show/NCT00978523?term=ar-12&rank=1

16. A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients with Metastatic Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00825487?term=arq+621&rank=1

17. A Phase I, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 out of 4 weeks in Subject with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00949559?term=ep-100&rank=1

18. An Open-Label, Phase I, Dose-Escalation Study of PI3 Kinase inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does not Exist or Has Proven Ineffective or Intolerable http://www.clinicaltrials.gov/ct2/show/NCT00876109?term=gdc0941&rank=3

19. A Phase I Open-label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genx-644282 in Patients with Advanced Malignant Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00942799?term=genz-644282&rank=1

20. A Phase 1 Study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies http://www.clinicaltrials.gov/ct2/show/NCT00761696?term=ipi926&rank=1

21. A Phase 1b/2a Safety and Pharmacokinetic Study of IT-101 in the Treatment of Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00333502?term=it101&rank=1

22. A Phase I Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, In Patients with Advanced Cancer (WEBSITE PENDING)

23. A Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in combination with Cisplatin in Adult Patients with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00648648?term=mk-1775&rank=1

24. A Phase I Dose Escalation Study of NKP-1339 in Patients with Advanced Solid Tumors Refractory to Treatment (WEBSITE PENDING)

25. A Phase 2 Dose Escalation Study of NMS-1286937 Administered to Adult Patients with Advanced/Metastatic Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT01014429?term=nms-1286937&rank=1
26. A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00738764?term=pdl192&rank=1

27. A Phase I, multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients with Advanced Solid Tumor http://www.clinicaltrials.gov/ct2/show/NCT00834704?term=PEGPH20&rank=1

28. A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Initial Dexamethasone Premedication Given Intravenously to Patients with Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show?term=pegph20&rank=2

29. A Phase I Study to Assess Safety, Pharmacakinetics, and Pharmacodynmaics of PLX3397 in Patients with Advanced, Incurable, Solid Tumor or Hematologic Malignancies in which the Target Kinases are linked to Disease Pathophysiology http://www.clinicaltrials.gov/ct2/show/NCT01004861?term=PLX3397&rank=1

30. A Phase I-Multi-Center, Open Label, Dose Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX93936 Administered Intravenously Daily for Five Days Followed by a 23 Day Rest Period in Patients With Advanced Solid Tumor http://www.clinicaltrials.gov/ct2/show/NCT00528047?term=PRLX+93936&rank=1

31. A Phase I Trial of Oral PX-478 (a HIF-1 Inhibitor) in Patients with Advanced Solid Tumors or Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00522652?term=PX-478&rank=1

32. A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, a MEK Inhibitor, in Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00610194?term=rdea119&rank=2

33. A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX 5422 Mesylate in Subjects with Refractory Solid Tumor Malignancies http://www.clinicaltrials.gov/ct2/show/NCT00506805?term=SNX-5422&rank=1

34. Phase 1 open labeled dose escalation study of VELIPARIB in combination with FOLFIRI in subjects with advanced Solid Tumors (WEBSITE PENDING)

35. A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Solid Tumors or Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00688415?term=VTX-2337&rank=1

36. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors http://www.clinicaltrials.gov/ct2/show/NCT00455052?term=XMT-1001&rank=1

    07/27/2010